GSK’s an­tibi­ot­ic suc­ceeds in late-stage gon­or­rhea tri­al with eye to ad­dress­ing re­sis­tance

GSK’s oral an­tibi­ot­ic gepoti­dacin has hit the pri­ma­ry end­point in a Phase III tri­al for uro­gen­i­tal gon­or­rhea, a grow­ing pub­lic health con­cern due to in­creased rates and emerg­ing re­sis­tance.

The EA­GLE-1 tri­al set gepoti­dacin against cef­tri­ax­one plus azithromycin in around 600 sub­jects with un­com­pli­cat­ed uro­gen­i­tal gon­or­rhea caused by Neis­se­ria gon­or­rhoeae. The drug can­di­date demon­strat­ed non-in­fe­ri­or­i­ty in the tri­al’s pri­ma­ry end­point, mi­cro­bi­o­log­i­cal re­sponse at the Test-of-Cure vis­it three to sev­en days af­ter treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.